August 17, 2021
Eisai said on August 16 that it has launched its EZH2 inhibitor Tazverik (tazemetostat) in Japan for the treatment of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma. Licensed from US biotech Epizyme, the drug is the first-in-class small molecule...read more